Lipid levels do not influence the risk of venous thromboembolism

Inge M. van Schouwenburg; Bakhtawar K. Mahmoodi; Ron T. Gansevoort; Friso L.H. Muntinghe; Robin P.F. Dullaart; Hanneke C. Kluin-Nelemans; Nic J.G.M. Veeger; Karina Meijer

doi:10.1160/TH12-06-0426

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2012; 108(05): 923-929
DOI: 10.1160/TH12-06-0426

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Lipid levels do not influence the risk of venous thromboembolism

Results of a population-based cohort study

Inge M. van Schouwenburg

¹Division of Haemostasis and Thrombosis, Department of Haematology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

,

Bakhtawar K. Mahmoodi

¹Division of Haemostasis and Thrombosis, Department of Haematology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

²Department of Nephrology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

,

Ron T. Gansevoort

²Department of Nephrology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

,

Friso L.H. Muntinghe

³Department of Vascular Medicine, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

,

Robin P.F. Dullaart

⁴Department of Endocrinology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

,

Hanneke C. Kluin-Nelemans

¹Division of Haemostasis and Thrombosis, Department of Haematology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

,

Nic J.G.M. Veeger

¹Division of Haemostasis and Thrombosis, Department of Haematology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

⁵Trial Coordination Centre, Department of Epidemiology, University of Groningen, University Medical Centre Groningen, The Netherlands

,

Karina Meijer

¹Division of Haemostasis and Thrombosis, Department of Haematology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

› Author Affiliations

Abstract

Summary

Studies on the association between lipid profile and venous thromboembolism (VTE) are inconsistent. This could be caused by classical lipoproteins being inferior to apolipoproteins as markers for VTE risk. Therefore, we examined whether apolipoproteins are more strongly related to VTE than lipoproteins. For this analysis we used the PREVEND prospective community based observational cohort study. Levels of apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), total cholesterol (TC), high-density lipoprotein (HDL), non-HDL, low-density lipoprotein (LDL), triglycerides (TG), lipoprotein(a), ApoB/ApoA1 and TC/HDL ratio were assessed. Subjects with VTE were identified using databases of the national registries of hospital discharge diagnoses, death certificates, and the regional anticoagulation clinic. Out of 7,627 subjects, 110 developed VTE during a median follow-up of 10.5 years. In both univariate and multivariable analyses no significant associations between apolipoproteins and overall VTE were observed. Of the classical lipoproteins, TC, non-HDL, LDL, TG, and TC/HDL ratio were significantly associated with overall VTE in univariate analysis. Significant associations were no longer present in multivariable analysis. TGL and LDL were significantly associated with unprovoked VTE in univariate analysis. After adjustment for age and sex this significance was lost. No significant associations between (apo-) lipoproteins and provoked VTE were found. We conclude that apolipoproteins are not better in predicting VTE risk than the classical lipoproteins. Our population-based cohort study does not show an association between both apolipoproteins and the classical lipoproteins and VTE risk.

Keywords

Venous thromboembolism - apolipoprotein - lipoprotein - lipid

Full Text

References

References
1 Becattini C, Vedovati MC, Ageno W. et al. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J Thromb Haemost 2010; 8: 891-897.
2 Glynn RJ, Danielson E, Fonseca FA. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-1861.
3 Grady D, Wenger NK, Herrington D. et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132: 689-696.
4 Ray JG, Mamdani M, Tsuyuki RT. et al. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001; 161: 1405-1410.
5 Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation 2010; 121: 1896-1903.
6 Tsai AW, Cushman M, Rosamond WD. et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182-1189.
7 Everett BM, Glynn RJ, Buring JE. et al. Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women. J Thromb Haemost 2009; 7: 588-596.
8 Deguchi H, Pecheniuk NM, Elias DJ. et al. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112: 893-899.
9 Doggen CJ, Smith NL, Lemaitre RN. et al. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 1970-1975.
10 von Depka M, Nowak-Gottl U, Eisert R. et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000; 96: 3364-3368.
11 Parish S, Peto R, Palmer A. et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J 2009; 30: 2137-2146.
12 McQueen MJ, Hawken S, Wang X. et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008; 372: 224-233.
13 Emerging Risk Factors Collaboration. Di Angelantonio E, Sarwar N. et al. Major lipids, apolipoproteins, and risk of vascular disease. J Am Med Assoc 2009; 302: 1993-2000.
14 Hillege HL, Janssen WM, Bak AA. et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-526.
15 Chobanian AV, Bakris GL, Black HR. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 2003; 289: 2560-2572.
16 Expert Committee on the Diagnosis and Classification of Diabetes.. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
17 Levey AS, Bosch JP, Lewis JB. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
18 Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem 2001; 47: 1579-1596.
19 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
20 Steinmetz J, Tarallo P, Fournier B. et al. Reference limits of apolipoprotein A-I and apolipoprotein B using an IFCC standardized immunonephelometric method. Eur J Clin Chem Clin Biochem 1995; 33: 337-342.
21 Survey Data Reference Manual Release 10. College Station, Texas: Stata Press; 2007
22 Bova C, Marchiori A, Noto A. et al. Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. A retrospective cohort study. Thromb Haemost 2006; 96: 132-136.
23 Prandoni P, Bilora F, Marchiori A. et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-1441.
24 Sorensen HT, Horvath-Puho E, Pedersen L. et al. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370: 1773-1779.
25 Yu-Poth S, Zhao G, Etherton T. et al. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr 1999; 69: 632-646.
26 de Lorgeril M, Renaud S, Mamelle N. et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343: 1454-1459.
27 Trichopoulou A, Costacou T, Bamia C. et al. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003; 348: 2599-2608.
28 Hansen-Krone IJ, Enga KF, Njolstad I. et al. Heart healthy diet and risk of myocardial infarction and venous thromboembolism. The Tromsø Study. Thromb Haemost 2012; 108: 554-560.
29 Steffen LM, Folsom AR, Cushman M. et al. Greater fish, fruit, and vegetable intakes are related to lower incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology. Circulation 2007; 115: 188-195.
30 Lutsey PL, Steffen LM, Virnig BA. et al. Diet and incident venous thromboembolism: the Iowa Women's Health Study. Am Heart J 2009; 157: 1081-1087.
31 Chamberlain AM, Folsom AR, Heckbert SR. et al. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood 2008; 112: 2675-2680.
32 Walldius G, Jungner I. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy. Nutr Metab Cardiovasc Dis 2007; 17: 565-571.
33 Griffin JH, Fernandez JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 2001; 86: 386-394.
34 Lacoste L, Lam JY, Hung J. et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-3177.
35 Ramcharan AS, Van Stralen KJ, Snoep JD. et al. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 2009; 7: 514-520.
36 Sen-Banerjee S, Mir S, Lin Z. et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 2005; 112: 720-726.
37 Ridker PM, Rifai N, Clearfield M. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-1965.
38 Ridker PM, Rifai N, Pfeffer MA. et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-235.
39 Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25: 287-294.
40 Naess IA, Christiansen SC, Romundstad P. et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5: 692-699.
41 Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83: 657-660.